News for RedHill Biopharma Ltd. (RDHL)

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., April 17, 2025 The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capita

RedHill Biopharma (RDHL) reported a stockholders' deficit of $4.68 million, below Nasdaq's required minimum of $2.5 million. The company has until May 3

Key Highlights:\n RedHill Biopharma (RDHL) posts a net loss of $8.3 million for 2024, a significant shift from the previous year's net income of $23.9 million

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., April 10, 2025 Revenue-generating with an exciting, diversified, largely externally funded, advanced develop

PR NewswireRALEIGH, N.C., March 18, 2025 RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process

PR NewswireRALEIGH, N.C. and TEL-AVIV, Israel, March 12, 2025 The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Cro

PR NewswireRALEIGH, N.C. and TEL-AVIV, Israel, Feb. 27, 2025 Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the Europe

PR NewswireTEL AVIV, Israel and RALEIGH, N.C., Feb. 25, 2025 - Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone pay

RedHill stock rises on expanded Medicare coverage

PR NewswireRALEIGH, N.C. and TEL-AVIV, Israel, Jan. 21, 2025 Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori ther

PR NewswireTEL-AVIV, Israel and RALEIGH, N.C., Dec. 2, 2024 RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgmen

The Ebola virus market is focused on developing vaccines and treatments to address outbreaks of this deadly virus. There are currently 18+ key companies...

Shares of Redhill Biopharma Ltd (RDHL) surged 9.81% in mid-day trading on Sep 9. The stock reached an intraday high of $10.35, before settling at $10.30, up

Opaganib shows promise in obesity, diabetes treatment

Stocks Analysis by Joel Latham covering: Eli Lilly and Company, Pfizer Inc, Redhill Biopharma Ltd, Corbus Pharmaceuticals Holding. Read Joel Latham's latest article on Investing.com

U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday. The Dow traded down 1.61% to 40,184.39 w...

The global increase in cancer cases is the main factor driving the demand for supportive care drugs. Additionally, the growing incidence of adverse effects...

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 500 points on Thursday. The Dow traded down 1.26% to 40,327.48 whil...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 1% on Thursday. The Dow traded up 0.03% to 40,853.73 while the NASDAQ r...